ANTENGENE-B (06996) Reports Interim Results with Adjusted Loss of RMB 72.858 Million, Down 52.25% YoY

Stock News

Aug 22

ANTENGENE-B (06996) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 53.182 million, representing a 12.5% year-on-year decrease. Research and development costs totaled RMB 79.935 million, down 38.91% compared to the same period last year. The adjusted loss for the period was RMB 72.858 million, a significant improvement of 52.25% year-on-year. Loss per share stood at RMB 0.12.

Revenue declined from RMB 60.8 million for the six months ended June 30, 2024, to RMB 53.2 million for the six months ended June 30, 2025, representing a decrease of RMB 7.6 million. In December 2023, Xpovio® (selinexor) was successfully included in the 2023 National Reimbursement Drug List. Due to positive market expectations, this initially drove strong market growth for the six months ended June 30, 2024. Subsequently, market demand gradually returned to rational levels.

Notably, revenue for the six months ended June 30, 2025, increased by RMB 22 million compared to the second half of 2024, reflecting steady revenue growth and stability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1193670443"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1193670443\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1193670443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-22 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193670443","market":"us","top_or_hot":-1,"title":"ANTENGENE-B (06996) Reports Interim Results with Adjusted Loss of RMB 72.858 Million, Down 52.25% YoY","media":"Stock News","content":"<p>ANTENGENE-B (06996) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 53.182 million, representing a 12.5% year-on-year decrease. Research and development costs totaled RMB 79.935 million, down 38.91% compared to the same period last year. The adjusted loss for the period was RMB 72.858 million, a significant improvement of 52.25% year-on-year. Loss per share stood at RMB 0.12.</p>\n<p>Revenue declined from RMB 60.8 million for the six months ended June 30, 2024, to RMB 53.2 million for the six months ended June 30, 2025, representing a decrease of RMB 7.6 million. In December 2023, Xpovio® (selinexor) was successfully included in the 2023 National Reimbursement Drug List. Due to positive market expectations, this initially drove strong market growth for the six months ended June 30, 2024. Subsequently, market demand gradually returned to rational levels.</p>\n<p>Notably, revenue for the six months ended June 30, 2025, increased by RMB 22 million compared to the second half of 2024, reflecting steady revenue growth and stability.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ANTENGENE-B (06996) Reports Interim Results with Adjusted Loss of RMB 72.858 Million, Down 52.25% YoY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nANTENGENE-B (06996) Reports Interim Results with Adjusted Loss of RMB 72.858 Million, Down 52.25% YoY\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-22 16:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ANTENGENE-B (06996) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 53.182 million, representing a 12.5% year-on-year decrease. Research and development costs totaled RMB 79.935 million, down 38.91% compared to the same period last year. The adjusted loss for the period was RMB 72.858 million, a significant improvement of 52.25% year-on-year. Loss per share stood at RMB 0.12.</p>\n<p>Revenue declined from RMB 60.8 million for the six months ended June 30, 2024, to RMB 53.2 million for the six months ended June 30, 2025, representing a decrease of RMB 7.6 million. In December 2023, Xpovio® (selinexor) was successfully included in the 2023 National Reimbursement Drug List. Due to positive market expectations, this initially drove strong market growth for the six months ended June 30, 2024. Subsequently, market demand gradually returned to rational levels.</p>\n<p>Notably, revenue for the six months ended June 30, 2025, increased by RMB 22 million compared to the second half of 2024, reflecting steady revenue growth and stability.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06996","symbol_name":"德琪医药-B","start_time":0,"source_url":"","article_id":"1193670443","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193670443","pubTimestamp":1755851902,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ANTENGENE-B (06996) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 53.182 million, representing a 12.5% year-on-year decrease. Research and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06996":"德琪医药-B","BK1583":"高瓴概念","BK1191":"制药","BK1574":"生物医药B类股"},"translate_title":"德琪医药-B(06996)公布中期业绩经调整亏损7285.8万元同比下跌52.25%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06996":1},"content_text":"ANTENGENE-B (06996) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 53.182 million, representing a 12.5% year-on-year decrease. Research and development costs totaled RMB 79.935 million, down 38.91% compared to the same period last year. The adjusted loss for the period was RMB 72.858 million, a significant improvement of 52.25% year-on-year. Loss per share stood at RMB 0.12.\nRevenue declined from RMB 60.8 million for the six months ended June 30, 2024, to RMB 53.2 million for the six months ended June 30, 2025, representing a decrease of RMB 7.6 million. In December 2023, Xpovio® (selinexor) was successfully included in the 2023 National Reimbursement Drug List. Due to positive market expectations, this initially drove strong market growth for the six months ended June 30, 2024. Subsequently, market demand gradually returned to rational levels.\nNotably, revenue for the six months ended June 30, 2025, increased by RMB 22 million compared to the second half of 2024, reflecting steady revenue growth and stability.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}